The Tech & Innovation Hub @ FUNanc1al

Tag: DIrector Buying

Cartoon DNA strand curling into a rocket blasting off from a beaker labeled ‘CRISPR Therapeutics,’ with smiling triglycerides fleeing the scene — symbolizing the company’s cholesterol-editing breakthrough

Will Gene Editing Stocks Ever Get Hot? If Not, Make Them CRISPR!

CRISPR Therapeutics (CRSP) just dropped jaw-dropping Phase 1 data: one IV treatment lowered triglycerides and LDL by up to 80%+ — safely. That’s not just biotech progress; it’s medical sci-fi turned reality. With insiders buying and gene-editing stocks heating up again, the question isn’t if CRISPR will change medicine — it’s whether it can change your portfolio.

Read entire article

Tags: Biotech Innovation, Biotech Stocks, Breakthrough Science, Buy or sell CRSP, CASGEVY, Cholesterol Management, Cholesterol Treatment, Crispr Therapeutics, CRSP, CRSP Stock, DIrector Buying, Director Insider Buying, Funanc1al Edge, FUNanc1al Humor, Funanc1al Investing, Gene Editing, Genomics, Healthcare Innovation, Insider Buys, Lowering Cholesterol, One Treatment, Statin Substitute, Stating